The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and will not be covered by social security. The main molecule in the medication is ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its ...

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%.

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...